Vir Biotechnology, Inc. · NASDAQ:VIR
Vir Biotechnology — Shareholder Meeting (May 2024)
12 slides from Vir Biotechnology's shareholder meeting presentation, May 14, 2024
Slide 1: 2024 Annual Meeting: Stockholder Engagement
2024 Annual Meeting: Stockholder Engagement Spring 2024 © 2024 Vir Biotechnology, Inc.™
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the near-term financial performance of Vir Biotechnology, Inc. (the “Company” or “Vi
Slide 3: Vir – Powering the Immune System to Transform Lives
Vir Biotechnology, which completed its IPO in 2019, is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir – Powering the Immune System to Transform Lives
Slide 4: A Significant Year of Transition
A Significant Year of Transition 2023 was a significant year of transition for Vir: multiple business challenges and sector headwinds impacted a strong start to the year, but our team delivered on key objectives, positioning us for success going forward Despite the unexpected business challenges in
Slide 5: Transformational Leader with Strong Track Record
Transformational Leader with Strong Track Record © 2024 Vir Biotechnology, Inc.™ Marianne De Backer, M.Sc., Ph.D., MBA Chief Executive Officer & Director Transformational leader with a track record of success in highly scientific and competitive therapeutic areas, a deep understanding of the evolvin
Slide 6: Refreshed Leadership Team Supporting Our Strategy
Refreshed Leadership Team Supporting Our Strategy © 2024 Vir Biotechnology, Inc.™ Eight of nine members of the leadership team are new to Vir or key executive roles since 2023 Marianne De Backer, M.Sc., Ph.D., MBA Chief Executive Officer (joined in 2023) Jeff Calcagno, M.D. EVP & Chief Business Offi
Slide 7: Compensation Decisions Facilitated Smooth Transition
Compensation Decisions Facilitated Smooth Transition © 2024 Vir Biotechnology, Inc.™ In connection with Dr. De Backer’s appointment as CEO, the Compensation Committee determined it necessary to grant targeted new-hire awards to incentivize De Backer to join Vir at a pivotal time CEO sign-on arrangem
Slide 8: Business-Aligned Executive Compensation Program
Business-Aligned Executive Compensation Program © 2024 Vir Biotechnology, Inc.™ Compensation program takes into account the volatility and uncertainty of our business as a clinical-stage biotech company, while also aligning incentives with long-term stockholder value and peer practices Component 202
Slide 9: Robust Engagement Informs Go-Forward Strategies
Robust Engagement Informs Go-Forward Strategies © 2024 Vir Biotechnology, Inc.™ In 2023, we proactively sought feedback from stockholders to understand key matters of interest as we continue to iterate our governance and compensation practices Preference for additional disclosure around the CEO tran
Slide 10: Experienced Board to Lead Vir Through Next Chapter
CONTINUING DIRECTORS (CLASSES I & III) Experienced Board to Lead Vir Through Next Chapter © 2024 Vir Biotechnology, Inc.™ Award-winning CEO with a proven record of accelerating the growth and impact of large pharma companies and helped bring important new therapeutics to patients around the world In
Slide 11: We Value Your Support
We Value Your Support The Board recommends FOR the election of the Company’s four director nominees 1 We request your support at the 2024 Annual Meeting of Stockholders The Board recommends FOR the approval on an advisory basis of named executive officer compensation 2 The Board recommends FOR the a
Slide 12: Additional Information and Where to Find It
© 2024 Vir Biotechnology, Inc.™ Additional Information and Where to Find It Vir Biotechnology, Inc. (“Vir”) has filed a definitive proxy statement and accompanying solicitation materials with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the solicitation of proxies for i